ライフサイエンスコーパス: Biacore

1 nce-based biomolecular interaction analysis (Biacore).

2 ssays and biomolecular interaction analysis (BIAcore).

3 kinetics (surface plasmon resonance using a BIACORE).

4 sexta BBMVs using surface plasmon resonance (BIAcore).

5 binding analysis using an optical biosensor (BIAcore).

6 MALDI-TOF MS and surface plasmon resonance (BIAcore).

7 tion analyses and surface plasmon resonance (Biacore).

8 and surface plasmon resonance studies using BIAcore.

9 inetics of ligand-receptor interaction using BIAcore.

10 tants that can be accurately determined from BIACORE.

11 t scFv from bacterial periplasm by koff in a BIAcore.

12 surface plasmon resonance measurements using Biacore.

13 54, in complex formation and stability using Biacore.

14 red by enzyme-linked immunosorbent assay and Biacore.

15 ntibody supernatants per day using automated Biacore 2000 and 3000 instruments.

16 se methods correlated with those obtained on Biacore 2000 and the absolute parameter values obtained

17 heparin by surface plasmon resonance using a BiaCore 2000 instrument.

18 designed for a serial processing instrument (Biacore 2000/3000/T100) and an array platform (Biacore F

19 nd confirmed with surface plasmon resonance (Biacore-2000); functional results were demonstrated usin

20 The BIACORE 3000 biosensor was used for the study and the so

21 cal protocol we had used with the MSPRS on a Biacore 3000 instrument using their bare gold chip.

22 Using a BIAcore 3000 optical biosensor, competition experiments

23 The autosampler in Biacore 3000 permitted whole cells expressing C-terminal

24 ancomycin (template) and characterized using Biacore 3000, dynamic light scattering, and electron mic

25 Bio-Rad's ProteOn XPR36, and GE Healthcare's Biacore 3000.

26 asmon resonance-based biosensor developed by Biacore AB (Uppsala, Sweden).

27 Using Biacore Flexchip (Biacore AB) surface plasmon resonance array-based biosen

28 Using Biacore analyses, we discovered that recombinant WxL pro

29 e scFv for binding to KDR were determined by BIAcore analysis (2.1 x 10(-9)-5.9 x 10(-9) M).

30 BIAcore analysis and competition binding assays using LO

31 es of five purified MoAbs were determined by BIAcore analysis and flow cytometric staining, and sever

32 BIAcore analysis demonstrated that, with the extracellul

33 Biacore analysis indicated that Stx2A1 has faster associ

34 thermodynamic constants determined from the Biacore analysis matched the values determined using iso

35 ry approaches of in vitro binding assays and BIAcore analysis revealed a high affinity association be

36 Unexpectedly, BIACORE analysis reveals that the SRI domain binds speci

37 and -3 were shown by immunoprecipitation and BiaCore analysis to bind to Robo1 but not Robo4.

38 Performing the Biacore analysis under mass transport limited conditions

39 Biacore analysis using peptide inhibitors and per-2 trun

40 By BIAcore analysis we demonstrate that Cry1Ab binds CR12-M

41 Kd, as defined by surface plasmon resonance (BIAcore analysis), and soluble CD74 inhibits MIF-mediate

42 the experimental variability associated with Biacore analysis, 36 different investigators analyzed a

43 In BIAcore analysis, IGFBP-2 and IGFBP-3 bound only to the

44 of core protein for gC1qR, as determined by BIAcore analysis, is 3.8 x 10(-7) M.

45 wo-hybrid analysis, immunoprecipitation, and Biacore analysis, we demonstrate that Evi5 binds Rab11a

46 oprecipitation and surface plasmon resonance/Biacore analysis, with an affinity in the low micromolar

47 of mAbs was assessed by Western blotting and BIAcore analysis.

48 ted by enzyme-linked immunosorbent assay and Biacore analysis.

49 antibodies for Ku86 was 16 nM as measured by BIAcore analysis.

50 ation of a DnaK-DnaJ complex as monitored by Biacore analysis.

51 0(7) and 1.5 x 10(7) M(-1), respectively, by BIAcore analysis.

52 Employing surface plasmon resonance (BIACORE) analysis, we found that recombinant versions of

53 anomolar range by surface plasmon resonance (Biacore) analysis.

54 constants were validated with SPR using both Biacore and fiber optic technology.

55 Biacore and flow cytometry assessment of the HP9-conjuga

56 nant expression and were characterized using BIAcore and flow cytometry.

57 Two biophysical methods, Biacore and KinExA, were used to kinetically and thermod

58 Orthogonal measurements obtained on Biacore and Octet label-free biosensor platforms further

59 sociation of drugs from liposome surfaces by Biacore and the lipid retention measurements determined

60 MP9 and BMP10) in surface plasmon resonance (Biacore) and cell-based assays.

61 Plasmon surface resonance (BIAcore) and competitive enzyme-linked immunosorbent ass

62 ic assay based on surface plasmon resonance (BIACORE) and formulated a curve-fitting model that takes

63 based on surface plasmon resonance studies (BIAcore) and the ability of soluble ALK-1 to block the a

64 nd biological activity as measured by ELISA, Biacore, and cell-based assays.

65 Western blot analysis, plasmon resonance by BIAcore, and endothelial cell proliferation assays to ch

66 Lewisx and Lewisx, as demonstrated by ELISA, BIAcore, and flow cytometry binding to the cell surface

67 A combination of NMR, BIAcore, and mutagenesis experiments was used to help id

68 ng and dissociation studies conducted with a BiaCore apparatus yielded an affinity of 350 pmol/L for

69 and rituximab in AR160 using peptide mapping/Biacore approach.

70 nance imaging systems, such as Flexchip from Biacore, are capable of monitoring hundreds of reaction

71 tolerant to competing drug in the assay, the Biacore assay detected developing Ab responses in 25 of

72 Additionally, the Biacore assay identified eight subjects who developed ne

73 n an enzyme-linked immunosorbent assay and a Biacore assay nor to any protein or DNA autoantigens tes

74 We have used a BIAcore assay to identify rodent and human cell conditio

75 The Biacore assay was more sensitive for detection of lower

76 and its binding affinity was confirmed in a Biacore assay.

77 e plasmon resonance biospecific interaction (BIAcore) assay showed the wild-type MVMp and MVMi capsid

78 Finally, using BIAcore assays we demonstrated that lipid-loaded saposin

79 had no effect on SIVmac239 binding to CD4 in Biacore assays, coimmunoprecipitation assays, and enzyme

80 R2 receptor with a submicromolar affinity in Biacore assays.

81 s of Jurkat cells and bind FasL in ELISA and BIAcore assays.

82 ant CD146 to Galectin-1 using both ELISA and Biacore assays.

83 tified through the described direct coupling Biacore assays.

84 L-18 with high affinity (K(D) 0.3-5 nM) in a BIAcore-based assay.

85 To explore the reliability of Biacore-based assays, 22 study participants measured the

86 In contrast with previous BIAcore-based estimates of very short half-lives for CD1

87 Furthermore, BIAcore (BIAcore, Piscataway, NJ) affinity measurements

88 orescence anisotropy, functional assays, and Biacore binding experiments to examine the effects of mu

89 aracterized by enzyme inhibition and NMR and Biacore binding experiments.

90 e of the hSRI domain to helices 1 and 2, and Biacore binding studies showed that the domain binds pre

91 Solid-phase and BIAcore binding studies showed that this fragment intera

92 The second immunoassay used a Biacore biosensor immunoassay format capable of detectin

93 A BIAcore biosensor instrument was used to determine the a

94 ermined by surface plasmon resonance using a BIAcore biosensor system.

95 Ab 2D7 for binding to the 2D7-2SK peptide in Biacore biosensor testing.

96 In the Biacore biosensor, a widely used tool for studying the k

97 brinogen was further characterized using the BIAcore biosensor.

98 BIACORE biosensors are useful for measuring reaction kin

99 es high-quality data near the sensitivity of Biacore but in a more multiplexed format.

100 the biosensor technology and illustrate how BIACORE can be used to study drug/HSA interactions in a

101 factor-alpha (TNFalpha), was investigated by BIAcore, cation exchange (CIEX), and size exclusion liqu

102 XCR5, a GPCR, was purified and captured on a Biacore chip surface via the affinity tag.

103 tavidin immobilized on a Pharmacia Biosensor BIAcore chip, and the tau binding activity of each alpha

104 el of binding site mutants are captured onto Biacore chips to enable characterization of the binding

105 sions immobilized on streptavidin-conjugated BIAcore chips.

106 al biological ligands, receptors, cells, and Biacore conditions, the binding layer will affect the in

107 mplified analysis of the adsorption stage of BIAcore data is presented in terms of the net observed p

108 The BIACORE data show an equilibrium dissociation constant o

109 a computer model that can generate realistic BIACORE data.

110 binding is sufficient to accurately analyze BIACORE data.

111 ncluding real-time interaction analyses with BIAcore, demonstrated that the affinity of the ERalpha i

112 n blot detected a very weak interaction, but BIAcore detected no measurable interaction between mVEGF

113 Using a specially designed peptide library, Biacore-detected protein-protein interaction, and adhesi

114 ably, surface plasmon resonance experiments (BIAcore) determined that DMAV binds sulfated glycosamino

115 Biacore experiments demonstrated that Hu007 and the type

116 step in the analysis of sensorgram data for BIAcore experiments is the subtraction of reference cell

117 VN variants were employed in BIAcore experiments to examine the uPAR-VN interaction i

118 xperiments and theory, it is not clear which Biacore experiments, if any, have transport within the d

119 Using Biacore Flexchip (Biacore AB) surface plasmon resonance

120 acore 2000/3000/T100) and an array platform (Biacore Flexchip) were used to examine how effectively 9

121 By monitoring the dissociation phase on Biacore for 4 h, we were able to measure dissociation ra

122 9.3, and 15 nM, respectively, as measured by Biacore for Fabs binding to RBD.

123 ity by immunohistochemistry, for affinity by BIACORE, for antibody-dependent cell-mediated cytotoxici

124 f commercial optical biosensors, such as the BIAcore from Pharmacia and IAsys from Affinity Sensors,

125 and the negatively charged C1 chip surface (Biacore, GE) generated a specific and stable immobilizat

126 Here, the BiaCore has been used to measure the kinetics and stoich

127 y used SPR analysis software, BIAevaluation (Biacore, Inc.), assumes that the RIIs of ligand and macr

128 Solution affinity data generated by BIAcore indicate this peptide binds to MBL with an affin

129 sured by surface plasmon resonance using the BIAcore instrument (Pharmacia Biosensor).

130 alysis of binding to immobilized CR1 using a BIAcore instrument documented that C1q, C4b, and C3b bin

131 plasmon resonance experiments (e.g., with a BIAcore instrument) have provided a valuable experimenta

132 surface plasmon resonance methodology with a BIAcore instrument.

133 strated by surface plasmon resonance using a BIACORE instrument.

134 Compared to previously released Biacore instruments, the most significant design change

135 molecule inhibitor-enzyme interactions using Biacore instruments.

136 ro by affinity enrichment chromatography and Biacore interaction.

137 agrees with that obtained from conventional Biacore kinetic analysis, and the stoichiometries for th

138 pseudo-first-order kinetic approximation of BIAcore kinetic data is likely to be heterogeneity of th

139 lonal antibody kinetics assays by a standard Biacore kinetics assay method with a simple low pH regen

140 The methodology was also extended to BIAcore measurements and implemented for ligands coupled

141 Biacore measurements established that the affinity of Al

142 Biacore measurements showed that these three HLA-A2 muta

143 BIAcore measurements using the purified, soluble scFvs y

144 ion and kinetic constants derived using this Biacore method are in excellent agreement with values de

145 We describe a general Biacore method for measuring equilibrium binding affinit

146 The Biacore method reported here provides an efficient way t

147 en monitored using a novel, highly sensitive BIACORE method, which allows measurement of human anti-h

148 mAb ABX-MA1 can result in false positives by Biacore methodology.

149 nzyme-Linked Immunosorbent Assay (ELISA) and BIACORE methods.

150 We show by quantitative yeast two-hybrid, BIAcore, NMR HSQC and STD, and confocal analyses that am

151 to monitor a Fab-antigen interaction using a BIACORE optical biosensor.

152 ng to the enzyme carbonic anhydrase II using Biacore optical biosensors.

153 using surface plasmon resonance technology (BIAcore, Pharmacia) often display kinetic behavior which

154 Furthermore, BIAcore (BIAcore, Piscataway, NJ) affinity measurements revealed

155 Biacore quantitative protein/protein interaction data, w

156 We validated our BIAcore results by comparing the same biological samples

157 CD8alphaalpha(f) for H-2K(b) as measured by BIAcore revealed a approximately 65 microM K(d), similar

158 mapping using surface plasmon resonance in a BIAcore revealed that the 28 scFv bound to only 4 nonove

159 For example, kinetic analysis (BIAcore) revealed that scFvs against staphylococcal ente

160 ic subunits (CVFh or C3b, or CVFn) using the BIAcore, revealed dissociation binding constants (Kd) th

161 with those from Biacore's flat C1 chip than Biacore's dextran-based CM4 chip.

162 based GLC chip agreed closer with those from Biacore's flat C1 chip than Biacore's dextran-based CM4

163 Using Biacore's new regenerateable streptavidin capture (CAP)

164 Using Biacore's surface plasmon resonance-based biosensor tech

165 peptides to compare the Octet directly with Biacore's well-established 3000 platform and Bio-Rad's r

166 Biacore S51 is a new surface plasmon resonance-based bio

167 to shuIL-4R alpha which was immobilized on a BIAcore sensor chip (K(d) = 46 pM).

168 nities of these systems were calculated from BIAcore sensorgrams.

169 Using both the BIAcore software analysis program and nonlinear regressi

170 test system, we validate the application of BIACORE SPR biosensors to reliably determine binding con

171 nteraction constants were determined using a Biacore SPR device (1:1 Langmuir binding model).

172 y optimisation was comparable with that of a BIAcore SPR system, an expensive laboratory gold standar

173 Using bSCP-2 immobilized on a Biacore streptavidin chip, we determined on- and off-rat

174 Flow cytometry, mass spectrometry, and Biacore studies demonstrated that the ILT3 ligand is a C

175 BIAcore studies indicated 6-fold tighter binding to c-Me

176 In surface plasmon resonance (BIAcore) studies, the designed peptides have been shown

177 termined kinetic data using a combination of BIAcore surface plasmon resonance (SPR) and dansyl-CaM f

178 Biacore surface plasmon resonance and differential scann

179 adherence to human salivary agglutinin by a BIAcore surface plasmon resonance assay.

180 es from hybridoma culture supernatants using Biacore surface plasmon resonance biosensor platforms.

181 Herein, Biacore surface plasmon resonance is used to identify an

182 which was determined by dose dependence and Biacore surface plasmon resonance testing.

183 The binding kinetics, as measured by BIAcore surface plasmon resonance, of monovalent Fab fro

184 Competition SPR experiments with the BIAcore system supported this observation.

185 olid-phase binding and an optical biosensor (BIAcore) system.

186 ive characterization of these Fabs shows how Biacore T100 can be used to complement protein therapeut

187 A Biacore T100 optical biosensor was used to characterize

188 Biacore T100 technology was used in conjunction with a v

189 generally similar to those collected using a Biacore T100, the AP-3000's stop-flow analyte delivery s

190 In addition, using the Biacore technique, we showed that this compound interact

191 rements and automated instrumentation, makes BIACORE technology applicable for evaluating drug/HSA in

192 that one would expect to observe when using Biacore technology for small molecule analyses.

193 findings along with the advantages of using Biacore technology to derive thermodynamic parameters in

194 e plasmon resonance (SPR) spectroscopy using BIAcore technology to evaluate biospecific interactions,

195 We used Biacore technology to measure directly the binding of na

196 Biacore technology was used to develop an affinity purif

197 were measured by surface plasmon resonance (Biacore) technology.

198 sine G-protein-coupled receptors, we applied Biacore to monitor receptor activity and characterize bi

199 se of a surface plasmon resonance biosensor (BIAcore) to compare triplex-directed binding of modified

200 mined by surface plasmon resonance analysis (BIAcore) to have a dominant component KD 535 +/- 24 nm.

201 surface plasmon resonance-based technology (BIAcore) to investigate the binding of recombinant AChBP

202 rent ratios in solution and then analyzed by Biacore using a sensor chip surface that detects only un

203 Biacore was used to determine KD = 6 x 10(-7) M between

204 of double-His6 GFP from Ni-NTA chips in SPR (BIAcore) was 10 times slower than for single-His6-tagged

205 Surface plasmon resonance (BIACORE) was used to determine the kinetic values for fo

206 Using surface plasmon resonance (BIAcore) we show that BMP-3 binds Activin Receptor type

207 Using BIACORE, we analyzed the ability of these U1A mutants to

208 Using real time interaction analysis with BIAcore, we evaluated the affinities and kinetics of the

209 mbinase and its specific target site loxP by BIACORE, we found that Cre associates with loxP tightly

210 fic interactions of immunogens, measured via BIAcore, were used to verify qualitatively a biosensor d

211 It was implemented on a commercial Biacore X SPR biosensor equipped with a microfluidic car

212 mercial surface plasmon resonance biosensor, BIACORE X, is employed as a detector in a closed loop of